米非司酮独用及与宫瘤消胶囊合用治疗子宫肌瘤的效果评价

Effect of Mifepristone Alone and Combined With Uterine Tumor Removing Capsule on the Treatment of Uterine Fibroids

目的探讨米非司酮独用及与宫瘤消胶囊合用治疗子宫肌瘤的临床效果。方法选择笔者所在医院2014年6月—2017年6月收治的子宫肌瘤患者共500例,根据随机法分为两组,对照组患者在对症治疗的基础上给予米非司酮口服治疗,观察组患者在对照组治疗的基础上给予宫瘤消胶囊,评价治疗前后的肿瘤体积和临床效果等指标。结果观察组患者干预后子宫肌瘤体积显著缩小,小于干预前和对照组干预后水平,差异有统计学意义(P<0.05),观察组患者临床有效率95.6%,高于对照组患者的70.0%,差异有统计学意义(P<0.05)。结论米非司酮与宫瘤消胶囊合用治疗子宫肌瘤的临床效果优于米非司酮独用,临床效果满意。

Objective To investigate the clinical effect of mifepristone alone and combined with uterine tumor removing capsule in the treatment of uterine fibroids. Methods 500 cases of uterine leiomyoma patients in our hospital from June 2014 to June 2017 were selected and randomly divided into two groups. Patients in the control group were given oral treatment of mifepristone on the basis of symptomatic treatment, patients in the observation group were given uterine tumor removing capsule on the basis of the treatment of control group. The tumor volume and clinical effect index were evaluated before and after treatment. Results The uterine fibroid volume of the patients in the observation group was significantly reduced after the intervention,significantly less than before intervention and control group, there were significant differences（P〈0.05）. The clinical efficiency was 95.6% in observation group and significantly higher than in the control group（70.0%）, with statistical significance（P〈0.05）. Conclusion The clinical effect of mifepristone combined with uterine tumor removing capsule in the treatment of uterine fibroids is superior to mifepristone alone, and the clinical effect is satisfactory.